If a patient is suffering from a Xarelto-related bleeding disorder and goes into an emergency room, there is no approved way to reverse the effects and little doctors can do help patients other than transfusing blood. The problem, as our Boston Xarelto attorneys understand, is there is a risk patients on the NAOC will develop internal bleeding disorders, including intracranial bleeding. NOACs such as Xarelto are marketed to Afib patients with claims they will not have to have their blood checked as often and lead a more normal life.
If a patient fails to have his or her blood checked and is taking an improper dose, they can suffer serious side effects. If the dosage is no longer correct, a patient’s doctor can adjust the dose. While effective, Warfarin patients need to have regular blood tests to make sure they are getting the correct dosage. Until the development of NAOCs, doctors would prescribe medications such as Warfarin to Afib patients. Blood clots can cause strokes and other dangerous conditions such as a pulmonary embolism (PE). Afib patients are a higher risk for serious diseases such as stroke and will typically be treated with a blood thinner to prevent serious clots from forming. The company claims Xarelto can help patients suffering from a condition known as atrial fibrillation (Afib). Janssen, a subsidiary of Johnson & Johnson, markets Xarelto. Xarelto is the brand name in the United States for rivaroxaban manufactured by Bayer AG. Other members of this class include Eliquis and Pradaxa. Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). It is hard to watch TV these days without seeing ads for Xarelto.
0 kommentar(er)
